Development of New Targeted Nanotherapy Combined with Magneto-Fluorescent Nanoparticles against Colorectal Cancer.
colorectal cancer
oral formulations
target drug delivery
target nanocarriers
targeted anticancer therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Apr 2023
01 Apr 2023
Historique:
received:
20
02
2023
revised:
28
03
2023
accepted:
29
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
The need for non-invasive therapies capable of conserving drug efficiency and stability while having specific targetability against colorectal cancer (CRC), has made nanoparticles preferable vehicles and principal building blocks for the development of complex and multi-action anti-tumoral approaches. For that purpose, we herein report the production of a combinatory anti-tumoral nanotherapy using the production of a new targeting towards CRC lines. To do so, Magneto-fluorescent NANO3 nanoparticles were used as nanocarriers for a combination of the drugs doxorubicin (DOX) and ofloxacin (OFLO). NANO3 nanoparticles' surface was modified with two different targeting agents, a newly synthesized (anti-CA IX acetazolamide derivative (AZM-SH)) and a commercially available (anti-epidermal growth factor receptor (EGFR), Cetuximab). The cytotoxicity revealed that only DOX-containing nanosystems showed significant and even competitive cytotoxicity when compared to that of free DOX. Interestingly, surface modification with AZM-SH promoted an increased cellular uptake in the HCT116 cell line, surpassing even those functionalized with Cetuximab. The results show that the new target has high potential to be used as a nanotherapy agent for CRC cells, surpassing commercial targets. As a proof-of-concept, an oral administration form of NANO3 systems was successfully combined with Eudragit
Identifiants
pubmed: 37047582
pii: ijms24076612
doi: 10.3390/ijms24076612
pmc: PMC10095016
pii:
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação para a Ciência e Tecnologia
ID : UIDB/50006/2020; UIDP/50006/2020; UID/QUI/50006/2013; POCI-01-0145-FEDER - 007265
Organisme : Fundação para a Ciência e Tecnologia
ID : PD/BD/142865/2018; 2022.09495.BD
Organisme : Fundação para a Ciência e Tecnologia
ID : CEECIND/00648/2017
Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : PID2021-127983OB-C22; MCIN/AEI/10.13039/501100011033
Références
J Enzyme Inhib Med Chem. 2013 Apr;28(2):311-5
pubmed: 22957724
Front Bioeng Biotechnol. 2021 Jul 07;9:670124
pubmed: 34307319
Radiother Oncol. 2011 Jun;99(3):424-31
pubmed: 21676479
Bioorg Med Chem. 2009 May 1;17(9):3295-301
pubmed: 19362844
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16233-8
pubmed: 19805286
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Drug Dev Ind Pharm. 2000 May;26(5):549-54
pubmed: 10789067
Int J Pharm X. 2019 Jul 19;1:100024
pubmed: 31517289
Eur J Med Chem. 2010 Nov;45(11):4769-73
pubmed: 20724038
J Enzyme Inhib Med Chem. 2011 Apr;26(2):231-7
pubmed: 20553118
Drug Deliv. 2022 Dec;29(1):664-678
pubmed: 35209786
Analyst. 2015 Feb 21;140(4):1221-8
pubmed: 25537483
Int J Mol Sci. 2020 Aug 10;21(16):
pubmed: 32785125
Bull Cancer. 1997 Jun;84(6):603-8
pubmed: 9295863
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465
pubmed: 30954567
J Drug Target. 2018 Sep;26(8):617-632
pubmed: 29095640
Blood Adv. 2023 Feb 28;7(4):529-532
pubmed: 35882475
Cancer Chemother Pharmacol. 1990;25(6):435-9
pubmed: 2311172
Theranostics. 2018 Jan 1;8(1):92-108
pubmed: 29290795
J Chem Inf Model. 2014 Aug 25;54(8):2371-9
pubmed: 24931227
Int J Cancer. 2003 Jul 20;105(6):873-81
pubmed: 12767076
Pharmaceutics. 2022 Feb 17;14(2):
pubmed: 35214167
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Int J Mol Sci. 2019 May 12;20(9):
pubmed: 31083645
Int J Pharm. 2008 Aug 6;360(1-2):47-52
pubmed: 18538518
Front Oncol. 2019 Sep 20;9:849
pubmed: 31616627
Int J Mol Sci. 2022 Oct 14;23(20):
pubmed: 36293142
Int J Nanomedicine. 2016 Jun 02;11:2491-504
pubmed: 27330292
Nanoscale. 2011 Oct 5;3(10):4314-22
pubmed: 21892492
Biomark Cancer. 2016 Sep 27;8:119-133
pubmed: 27721658
Biochim Biophys Acta. 2014 Feb;1840(2):838-46
pubmed: 23567800
Spectrochim Acta A Mol Biomol Spectrosc. 2012 Dec;99:150-9
pubmed: 23063858
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
J Enzyme Inhib Med Chem. 2008 Dec;23(6):895-900
pubmed: 18618324
Cancer Metastasis Rev. 2019 Jun;38(1-2):65-77
pubmed: 31076951
J Biol Chem. 2008 Jul 18;283(29):20473-83
pubmed: 18482982
Sci Total Environ. 2012 Dec 15;441:1-9
pubmed: 23134764
Int J Pharm. 2013 Sep 15;454(1):559-61
pubmed: 23850794
Eur J Pharm Sci. 2019 Oct 1;138:105019
pubmed: 31374253
Pathol Res Pract. 2019 Apr;215(4):705-711
pubmed: 30638861
Mol Cancer Ther. 2016 Dec;15(12):2926-2935
pubmed: 27609641
Biomater Sci. 2021 Mar 21;9(6):2279-2294
pubmed: 33538278
Metabolites. 2018 Feb 28;8(1):
pubmed: 29495652
IUCrJ. 2016 Feb 25;3(Pt 2):152-60
pubmed: 27006778
Front Chem. 2018 Nov 27;6:554
pubmed: 30538980
J Am Chem Soc. 2012 Sep 12;134(36):14726-9
pubmed: 22928733
Br J Cancer. 2009 Mar 24;100(6):874-80
pubmed: 19240720
J Control Release. 2017 Aug 10;259:187-194
pubmed: 27913308
Molecules. 2021 Jan 22;26(3):
pubmed: 33499047
Int J Mol Sci. 2021 Jun 08;22(12):
pubmed: 34201191
Materials (Basel). 2018 Jul 28;11(8):
pubmed: 30060598
Adv Sci (Weinh). 2022 Jan;9(1):e2102451
pubmed: 34773391
J Med Chem. 2006 Sep 7;49(18):5544-51
pubmed: 16942027
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Adv Drug Deliv Rev. 2020;157:63-70
pubmed: 32663488
Nat Rev Drug Discov. 2008 Feb;7(2):168-81
pubmed: 18167490
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
World J Gastroenterol. 2018 Sep 14;24(34):3834-3848
pubmed: 30228778
Drug Des Devel Ther. 2020 Oct 21;14:4387-4405
pubmed: 33116423
J Mater Chem B. 2016 Mar 28;4(12):2179-2189
pubmed: 32263185
Dis Colon Rectum. 2000 Aug;43(8):1133-40
pubmed: 10950013
Cell Biochem Biophys. 2015 Jul;72(3):757-69
pubmed: 27352189
Future Med Chem. 2015;7(11):1407-14
pubmed: 26230880
Expert Opin Pharmacother. 2016 Jul;17(10):1351-61
pubmed: 27156856
Bioorg Med Chem. 2008 Aug 1;16(15):7424-8
pubmed: 18579385
J Agric Food Chem. 2016 Mar 30;64(12):2627-34
pubmed: 26963935
Clin Colon Rectal Surg. 2020 Sep;33(5):298-304
pubmed: 32968365
Oxid Med Cell Longev. 2013;2013:972913
pubmed: 23766865
Materials (Basel). 2020 Jan 14;13(2):
pubmed: 31947551
Molecules. 2020 Nov 20;25(22):
pubmed: 33233669
Expert Opin Investig Drugs. 2018 Dec;27(12):963-970
pubmed: 30426805
Adv Drug Deliv Rev. 2019 Jun;146:248-266
pubmed: 29966684
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011